Gilenya beats Copaxone head-to-head at higher dose, study finds

Gilenya beats Copaxone head-to-head at higher dose, study finds

Submitted by admin on October 11, 2018 - 11:13pm
Source: 
Biopharma Dive
News Tags: 
Novartis
Teva Pharmaceutical
MS
Copaxone
Gilenya
Headline: 
Gilenya beats Copaxone head-to-head at higher dose, study finds
snippet: 

A high-stakes trial pitting Novartis' and Teva Pharmaceuticals' top-selling multiple sclerosis drugs head to head found the Swiss pharma's treatment to hold an efficacy edge.